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LG is a 49-year old woman with Down syndrome (DS). She and 3 other women with
intellectual disability live in a house in Delaware. These four women are assisted in their
activities of daily living by a small team of round-the-clock caregivers. LG used to need a
little help with zippers but chose her outfit and dressed herself. She needed some
assistance with food preparation but fed herself. Until early 2020, LG had spent the
previous 10 years attending a daily morning gathering with fellow residents after eating
a hearty breakfast. She loved pancakes and bacon. She was enthusiastic and friendly,
often first to sit and the first to share the expected weather for the day. She played tennis
two times a week and had done so for the past 20 years. In late 2019, LG started closing
her eyes during morning program and wasn’t the first to share the weather. She did not
want to participate in tennis and was easily frustrated by putting on the shoes she had
worn for several years, once throwing them across the room. Her balance was off and
she had a fall at the courts. After checking her sleep apnea treatment, her thyroid
function, her hearing and vision, LG was treated for depression. However, she started
eating fewer pancakes at breakfast. She would hold food in her cheek for far too long and
lost a small amount of weight as a result. She spoke much more quietly and often would
shake her head yes or no when asked a question without a verbal reply. Her eyes were
closed for much of the morning though she was awake.
Both LG’s family and health care team asked whether the changes we saw could all be from
depression. What else could be going on and what would be LG’s expected course? What
workup and management should follow? We considered Alzheimer’s dementia. Down syndrome
(DS), caused by an extra copy of the twenty-first chromosome, is a significant risk factor for
early onset Alzheimer’s dementia (AD). The mechanism is believed to be linked to
overproduction of amyloid precursor protein (APP) linked to the extra copy of the twenty-first
chromosome, with subsequent development of amyloid plaques and neurofibrillary tangles in the
brain.1 Given the increase in lifespan for individuals with DS from the mid 20’s in the 1980s to
60 today, the number of older Americans with DS is increasing and members of the health care
team need to better understand the unique characteristics of these individuals in order to optimize
best practices for care.2,3 We will review common characteristics and co-morbidities of
individuals with DS, review the epidemiology of AD and clinical presentation of AD in this
cohort, discuss practical considerations for diagnosis and treatment as well as strategies to
maximize support for caregivers. Consistent with the National Plan to Address Alzheimer’s
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Disease, we will focus on the importance of the early detection of AD and what it means to
patients, caregivers, and the healthcare system.

Down Syndrome
DS is the most common genetic cause of intellectual disability (ranging from mild to severe) and
is associated with a number of common medical conditions including hypothyroidism, sleep
apnea, vision and hearing abnormalities, seizure disorders, dental disease, autism, and mental
health issues.3,4 The first evidence-based guidelines for adults with DS were only recently
published and provide guidance on best practices for care of this vulnerable population, and also
highlight the need for further research given the limited quality of the available evidence.2 The
strongest recommendation from the guidelines is a strong recommendation to screen adults with
DS for AD beginning at age 40 with a dual purpose of identifying AD along with potentially
treatable medical conditions that may appear to be AD or contribute to functional decline.2 It is
estimated that approximately 30% of adults with DS in their 50s and 50% of those in their 60s
have AD. The average age for AD diagnosis in DS is 55. Clinical AD appears to be rare in
individuals with DS prior to the age of 40, and experts urge caution in making a diagnosis prior
to this age.2,3

What Does AD Look Like in Patients with DS?
While some experts suggest that the later stages of AD in people with DS are similar to the
general population of people with AD, the early stages of AD in DS are very variable.5 In a
recent systematic review, “frontal-like symptoms” such as changes in fearfulness, lack of energy,
withdrawal, disinhibition, and sadness were cited as the most common presentation of AD in
people with DS. Changes in memory were reported less consistently. This may be in part due to
baseline impairments in working memory in individuals with DS related to function of the
hippocampus versus universal decline in working memory skills as a part of “normal” aging in
DS. Gait dyspraxia (difficulty initiating walking or making turns, shuffling, fear and avoiding of
obstacles such as stairs) and new onset seizures can be early markers of cognitive decline.6

Diagnosing Mild Cognitive Impairment (MCI-DS) and AD in Patients
with DS
The most commonly used screening tool for evaluating the early indicators of dementia in DS is
the National Task Group – Early Detection Screen for Dementia (NTG-EDSD).7 The instrument
contains both signal items associated with an increased risk of AD (unexpected problems with
memory, getting lost, gait changes, new seizures, confusion in familiar settings, personality
change) and 51 questions in six cognitive or functional domains - Activities of Daily Living
(ADL), Language, Sleep-Wake Change Patterns, Ambulation, Memory, and Behavior and
Affect. In evaluating the sensitivity of the NTG-EDSD specifically for the detection of MCI-DS,
the authors highlight some of the difficulties in using the instrument clinically, which include a
lack of consensus with respect to the diagnostic criteria for MCI-DS beyond a decline in
cognitive abilities worse than expected for age, and for AD in DS in general since there are a
lack of population-based standards.7 The NTG-EDSD scoring scale helps clinicians compare
patients with DS to their own baseline as the questions are scored always been the case, always
but worse, new symptom in the past year, or does not apply. The framework of analysis reflects
transitions from “clinically stable” to concern for MCI-DS to suspicious for AD.
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One or more new concerns in the domains of Language and Memory appear to distinguish
individuals who are cognitively stable vs. those with probable early AD (Sensitivity = 0.895 and
Specificity = 0.802) or MCI-DS (Sensitivity = 0.806 and Specificity = 0.802).7 In practical terms
for the busy clinician, the authors of this study suggest that the likelihood is extremely high that
an individual with five or more concerns in the domains of Language and Memory has MCI-DS
or AD and is high if there is at least one concern. In contrast, those with no concerns in the
Language and Memory domain or few concerns overall or in signal items have a low likelihood
of MCI-DS or AD. Using a criterion of five or more concerns overall, the study found a
sensitivity of 0.868 for dementia (vs 0.417 for MCI-DS) with a specificity of 0.802.7

Clinical Evaluation in Aging Patients with DS
Annual assessment of thyroid function and periodic assessment for risk of sleep apnea are
important in the lifespan care of individuals with DS. A decline in mean verbal IQ and decreased
cognitive flexibility is seen in individuals with DS and untreated OSA.8 In patients with DS
where there are concerns for functional decline other conditions to consider are depression,
anxiety, vision/hearing changes, Vitamin B12 deficiency, celiac disease, structural heart disease,
seizure disorder, polypharmacy, diabetes, kidney disease, or urinary tract infection. Somewhat
unique to individuals with DS is atlantoaxial instability (AAI) presenting as functional decline.
In general, the risk of AAI is much higher in younger individuals than older individuals with DS
but can present as change in gait, handedness, or functional decline. Individuals with DS may
have difficulty expressing pain due to challenges with communication but this possibility should
be explored. Validated scales for depression or anxiety do not exist for individuals with DS so
clinicians have to be clinically suspicious and need to consider therapeutic trials as part of their
diagnostic work up. Constipation is extremely common in individuals with DS and needs to be
considered.

Treatment Strategies
Pharmacotherapy has shown little promise in the prevention or treatment of AD in patients with
DS although the evidence is of low quality. Clinicians can consider a trial of medications to
postpone expression of symptoms and to improve function slightly, but need to monitor for side
effects.9 Pharmacotherapy and non-pharmacologic approaches to treat co-existing depression and
anxiety, and improve quality of life are important considerations in the care of patients with AD
and DS. Cognitive enhancers such as donepezil or rivastigmine are the only drugs approved by
the FDA for the treatment of AD investigated in individuals with Down syndrome (DS).
Symptom specific therapy may be necessary if a patient is impulsive or aggressive; both
stimulant and antipsychotic medications may be used on an “off-label” basis (based on evidence
but not FDA indication) in low doses respectively.

Role of the Interprofessional Team in the Care of Patients with Known
or Suspected MCI-DS or AD
Caring for and supporting patients with DS and MCI-DS and AD is best managed from an
Interprofessional team approach to achieve the best outcomes.10,11 Patients with DS and MCI-DS
or AD may demonstrate changes in behavior, personality, emotional responses and/or affect as
well as difficulty with familiar activities such as self-care or decreased participation in activities
they used to enjoy as the condition worsens. This can be stressful for caregivers when strategies
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that have been successful in supporting the patient with DS are no longer working.12 Having a
network of Interprofessional providers with expertise in addressing these changes can help
families and caregivers prepare for “next steps,” integrate adaptations to help the patient remain
age in place and implement strategies to improve the quality of life for the patient and the
caregivers.13 Social workers, case managers, nurses and occupational therapists can evaluate the
needs of the patient and caregiver and provide recommendations to support patient participation
in activities and routines which can improve patient overall health and well-being as well as
reduce unwanted behaviors. Several national resources are available to provider information and
resources on best practices in supporting patients with DS and MCI-DS and AD. Closer to home,
regional and local resources with expertise in supporting patients with DS can provide more
specific consultation and support tailored to the individual patient and caregiver needs.
The role of primary care becomes apparent when health disparity is demonstrated.14 As the mean
age of survival for an individual with DS stretches to 60 years and beyond, the need for
appropriate cancer screening is all the more relevant.15 Those with intellectual and
developmental disabilities (IDD) are not screened for breast, colon, prostate, and cervical cancer
at the rates of their similar-aged peers without IDD. Thus, higher morbidity and mortality result.
During the COVID-19 pandemic, those with IDD had higher risk of contracting, and also
becoming sick and dying from the virus.16 The goal of the primary care physician is to recognize
and manage the medical and socioeconomic disparity that exists for patients with DS, especially
as they age. In the case of patients with DS and dementia, understanding the living situation, who
speaks for the individual when they cannot speak for themselves, recognizing the potential for
injury and abuse—all while providing quality health care—takes an interprofessional team.

Emerging Research
The Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS) is a NIH-funded
research initiative to evaluate the effectiveness of biomarkers for both diagnosis and prognosis.
PET Scan is being studied for its role in both diagnosis and prognosis. Amyloid PET is positive
in nearly all individuals with DS by the age of 40 given the uniform presence of plaques and
tangles, so is not helpful in diagnosis or prognosis, but Tau PET may play a role. In 2018, the
NIH launched the INCLUDE project (Investigation of Co-occurring conditions across the
Lifespan to Understand Down syndrome) which funds multiple studies to address general health
and quality-of-life needs for people with DS. Improving baseline health status and inclusive
health practices that address health disparities may have a protective role or delay the onset of
clinically significant signs and symptoms of AD.
LG’s NTG-EDSD was suspicious for AD. She was started on donepezil but had diarrhea
that was not improved by diet, other medications, and changing the timing of
administration. Her case manager was instrumental in engaging LG in one on one
smaller activities and a nutritionist helped plan 4-5 mini meals a day which LG enjoys.
Her weight has stabilized though she continues to pocket food and her diet was
downgraded to a minced and moist consistency to make it easier to chew. She goes for a
walk once a day with a walker, sometimes on the tennis courts. She keeps her eyes open
when she is chair dancing; music and singing are the most effective treatments for her
withdrawal and lack of verbal response. Though the pandemic decreased her
opportunities for engaging in community activities outside of her home, at the time of this
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writing, she was enjoying her first live music experience with friends on a sunny patio in
her town.
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